A Phase 3 interventional study of multimodal Resilience© digital companion and Standard supportive care in Breast Cancer and Breast Cancer Early Stage Breast Cancer (Stage 1-3), sponsored by Gustave Roussy, Cancer Campus, Grand Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.
Sponsored by Gustave Roussy, Cancer Campus, Grand Paris · Phase 3, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Breast Neoplasms by Gustave Roussy, Cancer Campus, Grand Paris — 8 open to participants now, 9 under way, 3 of them phase 3. Breast Neoplasms · Gustave Roussy, Cancer Campus, Grand Paris.
Among the 20 studies in Breast Neoplasms by Gustave Roussy, Cancer Campus, Grand Paris, this one is the 6th largest by planned enrollment, is one of 2 that started in 2025, is one of 6 in phase 3, and was the 16th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →8 of the 20 studies in Breast Neoplasms by Gustave Roussy, Cancer Campus, Grand Paris are open now, in 1 country. Recruiting first, the newest first:
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+ · Women only
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 6 · Phase 4 1
First in 2009; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 140 across the 20 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gustave Roussy, Cancer Campus, Grand Paris is the lead sponsor of 245 studies on the registry; 66 are open to participants now.
5 of the studies in Breast Neoplasms by Gustave Roussy, Cancer Campus, Grand Paris that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06787118Phase 3Gustave Roussy, Cancer Campus, Grand ParisStudy Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer | 2027-05 |
| NCT07159451Gustave Roussy, Cancer Campus, Grand ParisA Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer | 2027-01-29 |
| NCT04965766Gustave Roussy, Cancer Campus, Grand ParisPatritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer | 2027-04-11 |
| NCT06298084Gustave Roussy, Cancer Campus, Grand ParisDose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | 2027-09 |
| NCT07436312Gustave Roussy, Cancer Campus, Grand ParisImpact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 20 studies in Breast Neoplasms by Gustave Roussy, Cancer Campus, Grand Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Randomized trial that compares a personalized digitally-enabled pathway delivered by a mobile application in addition to standard of care vs. standard of care alone in patients with HR+ early breast cancer reporting endocrine therapy related adverse events.
The HOPE study is a national, prospective, randomized, open-label trial conducted in France. 180 patients will be randomly assigned 1:1 to receive either 12 weeks of multimodal Resilience© digital companion including education and self-care modules in addition to the standard of care provided by their treating oncologists and supportive care team at their care centers or 12 weeks of standard of care provided by their treating oncologists and supportive care team at their care centers.
Data from the literature in oncology trials with Patient-Reported Outcomes suggests that in the absence of double-blind concealment, clinically important differences could still be detected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documentation of Disease:
NB: Bilateral breast carcinoma is allowed;
NB: Patients with personal history of previous breast cancer or Ductal Carcinoma in situ (DCIS) are eligible for the protocol;
Others:
NB: Patients may have breast reconstruction during protocol participation;
NB: Biologic therapy, targeted therapy and bisphosphonates are acceptable during protocol participation;
NB: Male patients can be included in the trial;
NB: Pharmacological or other non-pharmacological interventions for endocrine treatment for adverse effects are accepted at physician discretion.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will receive standard of care provided by the oncologist and supportive care team at the patient local cancer center including referrals for local supportive care programs. In addition, patients will have access to Resilience© a multi-component, multi-level interventional mobile application that will offer: (a) supportive educational care information (b) self-symptom management resources with availability of a remote health-care provider evaluation that addresses patient-specific needs in survivorship care and recommends personalized digital self-management resources at onboarding and if needed in case of low engagement in the mobile app.
Other: multimodal Resilience© digital companion · Other: Standard supportive care
Patients will receive standard of care provided by the oncologist and supportive care team at the patient local cancer center including referrals for local supportive care programs. Local supportive care programs may also include the use of already deployed remote patient monitoring and solutions, digital and in person education.
Other: Standard supportive care
Resilience© is a multi-component, multi-level interventional mobile application that will offer: (a) supportive educational care information (b) self-symptom management resources with availability of a remote health-care provider evaluation that addresses patient-specific needs in survivorship care and recommends personalized digital self-management resources at onboarding and if needed in case of low engagement in the mobile app. Intervention duration : 3 weeks
standard of care provided by the oncologist and supportive care team at the patient local cancer center including referrals for local supportive care programs. Local supportive care programs may also include the use of already deployed remote patient monitoring and solutions, digital and in person education.
To determine the efficacy of a personalized approach, consisting of a multi-component, interventional mobile application in addition to standard of care, compared with standard care alone in improving quality of life (QOL) after 12 weeks.
The primary endpoint of the study is the ET symptoms scale of the European Organization for Research and Treatment of Cancer (EORTC) QOL questionnaire (QLQ)-BR45 over a 12-weeks period.
Time frame: up to 12 weeks of intervention
To evaluate the impact of the intervention on other EORTC QLQ-C30 domains, including fatigue, emotional distress, pain, and sleep quality;
Time frame: after 12 months of randomization
To evaluate the impact of the intervention on insomnia measured by a wearable device;
Insomnia by a wearable device capturing sleep quality and sleep cycle (Withings© Pulse HR smartwatch);
Time frame: up to 12 months after randomization
To evaluate the impact of the intervention on adherence to endocrine therapy, assessed through the modified MIS-A questionnaire
reliable, easy-to-use, self-administered questionnaire, validated in France that is able to longitudinally capture granular data on non-adherence to chronic medication over short and long time.
Time frame: up to 12 months after randomization
To evaluate the impact of the intervention on the perceived self-efficacy of symptom management;
Perceived self-efficacy in symptom management will be evaluated using the PROMIS Self-Efficacy for Managing Chronic Conditions - Managing Symptoms - Short Form 8a questionnaire.
Time frame: up to 12 months after randomization
To evaluate the impact of the intervention on eHealth Literacy levels
Ability of the patients to find, understand and use information to improve their health from electronic sources using the eHLQ questionnaire
Time frame: up to 12 months after randomization
To evaluate the implementation process including the adoption of the HOPE digitally enabled supportive care pathway (Resilience mobile application)
Information on digital health adoption and implementation process will be measured by different criteria: \- Willingness rate (Resilience© digital companion): will be defined as the rate of patients that activated a Resilience account adoption rate (Resilience© digital companion): will be defined as the rate of users who used Resilience as intended Full digital usage experience: using the experience questionnaire developped for the study
Time frame: up to 12 weeks of intervention
To evaluate the patient experience in using a web platform (WeShare) for collecting ePROs data.
Using the experience questionnaire developped for the study and the French System Usability Scale
Time frame: up to 12 weeks of intervention
To evaluate the impact of the intervention on physical activity levels measured by a wearable device;
Physical activity levels will be captured through a wearable device (number of steps, distance in Km and calories burned) (Withings © Pulse HR smartwatch)
Time frame: up to 12 weeks of intervention
Started Sep 2025 (actual). Primary completion is estimated for Mar 2026, 6 months after the start.
Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 6 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gustave Roussy, Cancer Campus, Grand Paris →